Richard A. Fair insider trades: Bellicum Pharmaceuticals (BLCM) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Richard reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 17, 2020 | BLCM | ↑ Buy | 5,000 | $4.00 | $20K | By Trust | Mar 19, 2020 (2d) |
| Sep 10, 2019 | BLCM | ↑ Buy | 40,000 | $1.25 | $50K | Direct | Sep 11, 2019 (1d) |
| Aug 21, 2019 | BLCM | ↑ Buy | 20,000 | $0.99 | $20K | Direct | Aug 23, 2019 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Richard A. Fair's insider trades
Richard A. Fair is President and CEO at Bellicum Pharmaceuticals (BLCM). Since Aug 21, 2019, Richard has reported 3 open-market purchases worth $90K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BLCM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.